| Improvement of signs and symptoms of nonradiographic axial spondyloarthritis in patients treated with secukinumab: primary results of a randomized, placebo‐controlled phase III … A Deodhar, R Blanco, E Dokoupilová, S Hall, H Kameda, AJ Kivitz, ... Arthritis & Rheumatology 73 (1), 110-120, 2021 | 123 | 2021 |
| Validity and reliability of the Fatigue Severity Scale in Finnish multiple sclerosis patients E Rosti‐Otajärvi, P Hämäläinen, A Wiksten, T Hakkarainen, J Ruutiainen Brain and behavior 7 (7), e00743, 2017 | 99 | 2017 |
| Hartung–Knapp method is not always conservative compared with fixed‐effect meta‐analysis A Wiksten, G Rücker, G Schwarzer Statistics in medicine 35 (15), 2503-2515, 2016 | 74 | 2016 |
| Occurrence of pressure ulcers and risk factors in a mixed Medical-Surgical ICU—a cohort study MH Ahtiala, ET Soppi, A Wiksten, H Koskela, JA Grönlund Journal of the Intensive Care Society 15 (4), 340-343, 2014 | 31 | 2014 |
| Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT J Braun, R Blanco, H Marzo-Ortega, LS Gensler, F Van den Bosch, S Hall, ... Arthritis research & therapy 23 (1), 1-10, 2021 | 28 | 2021 |
| Secukinumab improves signs and symptoms of non-radiographic axial spondyloarthritis: primary results of a randomized controlled phase III study. A Deodhar, R Blanco, E Dokoupilová, S Hall, H Kameda, AJ Kivitz, ... Arthritis & Rheumatology (Hoboken, NJ), 2020 | 25 | 2020 |
| Nonproportional hazards in network meta-analysis: efficient strategies for model building and analysis A Wiksten, N Hawkins, HP Piepho, S Gsteiger Value in Health 23 (7), 918-927, 2020 | 23 | 2020 |
| Validity and reliability of the Finnish version of the Multiple Sclerosis Impact Scale‐29 E Rosti‐Otajärvi, P Hämäläinen, A Wiksten, T Hakkarainen, J Ruutiainen Brain and Behavior 7 (7), e00725, 2017 | 23 | 2017 |
| Estimating relative efficacy in acute postoperative pain: network meta-analysis is consistent with indirect comparison to placebo alone RA Moore, S Derry, PJ Wiffen, S Banerjee, R Karan, E Glimm, A Wiksten, ... Pain 159 (11), 2234, 2018 | 13 | 2018 |
| Secukinumab 150 mg significantly improved signs and symptoms of non-radiographic axial spondyloarthritis: 52-week results from the phase III PREVENT study J Braun, R Blanco, E Dokoupilova, LS Gensler, A Kivitz, S Hall, H Kameda, ... ANNALS OF THE RHEUMATIC DISEASES 79, 69-70, 2020 | 7 | 2020 |
| OP0106 secukinumab 150 mg significantly improved signs and symptoms of non-radiographic axial spondyloarthritis: 52-week results from the phase iii prevent study J Braun, R Blanco, E Dokoupilova, LS Gensler, A Kivitz, S Hall, H Kameda, ... Annals of the Rheumatic Diseases 79 (Suppl 1), 69-70, 2020 | 4 | 2020 |
| Secukinumab Improved Signs and Symptoms in Patients with Non-radiographic Axial Spondyloarthritis: Results from a Randomized Controlled Phase III Study Stratified by Baseline … J Braun, R Blanco, H Marzo-Ortega, L Gensler, F Van den Bosch, ... ARTHRITIS & RHEUMATOLOGY 72, 2020 | 2 | 2020 |
| Le sécukinumab améliore les signes et symptômes de la spondyloarthrite axiale non radiographique: résultats d’une étude de phase III randomisée, contrôlée, stratifiée sur les … P Goupille, J Braun, R Blanco, H Marzo-Ortega, L Gensler, ... Revue du Rhumatisme 87, A175-A176, 2020 | | 2020 |
| SECUKINUMAB SIGNIFICANTLY IMPROVED SIGNS AND SYMPTOMS OF NON-RADIOGRAPHIC AXIAL SPONDYLOARTHIUTIS: 16-WEEK RESULTS FROM THE PHASE-III PREVENT STUDY A Deodhar, R Blanco, E Dokoupilova, M van de Sande, S Hall, A Wiksten, ... JCR-JOURNAL OF CLINICAL RHEUMATOLOGY 26, 79-80, 2020 | | 2020 |
| Non-Proportional Hazards in Network Meta-Analysis: Efficient Strategies for Model Building and Analysis S Gsteiger, R Windisch, P Bryden, A Wiksten Value in Health 20 (9), A402, 2017 | | 2017 |
| Occurrence of pressure ulcers and risk factors in a mixed medical-surgical ICU—a cohort study 3C00 M Ahtiala, E Soppi, A Wiksten, H Koskela, JA Grönlund Knee 3, 2.6, 0 | | |
